Study of TLR9 Agonist CMP-001 in Combination With Nivolumab vs. Nivolumab
Status:
Recruiting
Trial end date:
2028-07-30
Target enrollment:
Participant gender:
Summary
The main goal of this research study is to determine how nivolumab and nivolumab/CMP-001
combination affect the likelihood of destroying melanoma involving lymph node and/or
in-transit/satellite areas.
The main goal of the PET/CT scan with 18F]F-AraG is to evaluate how [18F]F-AraG uptake
changes before and after administration of either nivolumab or nivolumab/CMP-001 combination.
Phase:
Phase 2
Details
Lead Sponsor:
Diwakar Davar
Collaborators:
CellSight Technologies, Inc. Checkmate Pharmaceuticals